Who are Niacin plus laropiprant's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comparator: niacin + laropiprant.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/niacin-plus-laropiprant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Niacin plus laropiprant — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Niacin plus laropiprant (Niacin plus laropiprant) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lipid-modifying agent combination. Area: Cardiovascular.

marketed Lipid-modifying agent combination DP1 receptor (laropiprant component); niacin acts on GPR109A and other pathways Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Niacin plus laropiprant (Niacin plus laropiprant) — Institut Investigacio Sanitaria Pere Virgili. Niacin raises HDL cholesterol and lowers triglycerides, while laropiprant blocks prostaglandin D2 receptors to reduce niacin-induced flushing.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Niacin plus laropiprant TARGET	Niacin plus laropiprant	Institut Investigacio Sanitaria Pere Virgili	marketed	Lipid-modifying agent combination	DP1 receptor (laropiprant component); niacin acts on GPR109A and other pathways
Comparator: niacin + laropiprant	Comparator: niacin + laropiprant	Merck Sharp & Dohme LLC	phase 3	Lipid-modifying agent combination	Niacin: GPR109A (hydroxycarboxylic acid receptor 2); Laropiprant: DP1 (prostaglandin D2 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lipid-modifying agent combination class)

Institut Investigacio Sanitaria Pere Virgili · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Niacin plus laropiprant — Competitive Intelligence Brief. https://druglandscape.com/ci/niacin-plus-laropiprant. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing